You are here

Home » Content

Ankilozan Spondilitli Hastalarda Etanercept Tedavisinin Etkinliği ve Güvenilirliği

Efficacy and Safety of Etanercept in Patients with Ankylosing Spondylitis

Journal Name:

  • İnönü Üniversitesi Tıp Fakültesi Dergisi

Publication Year:

  • 2010

Key Words:

Keywords (Original Language):

Author NameUniversity of AuthorFaculty of Author
Abstract (2. Language): 
Objective: The aim of this study was to evaluate efficacy and safety of etanercept in patients with ankylosing spondylitis (AS). Material and Methods: 21 patients with AS were evaluated before and after 6 months of etanercept treatment based on the clinical and laboratory parameters. Clinical efficacy was determined using criteria defined by the asessment in AS (ASAS) International Working Group (ASAS-20 ASAS-40, ASAS-5/6, and ASAS partial remission) and BASDAI-50 responses. Results: There were statistically significant improvements in all clinical and laboratory parameters after the six months of etanercept treatment (p <0.001). Additionally, ASAS-20 was achieved in 18 of 21 patients. ASAS-40, ASAS-5/6, ASAS partial remission and BASDAI-50 were achieved in 16, 13, 10 and 16 patients, respectively. None of the patients withdrew from etanercept treatment because of serious adverse effect. Injection site reaction in 4, erythema in 1, and nausea and vomiting in 1 patients were observed throughout of the study. Conclusion: Our results demonstrated that etanercept treatment was safe and effective in AS patients.
Bookmark/Search this post with
Abstract (Original Language): 
Amaç: Bu çalışmanın amacı; ankilozan spondilit (AS)’li hastalarda etanercept tedavisinin etkinliğini ve güvenilirliğini araştırmaktır. Gereç ve Yöntem: 21 AS’li hasta tedavi öncesi ve 6 aylık tedaviden sonra klinik ve laboratuvar parametrelerle değerlendirildi. Tedavinin etkinliği ayrıca Uluslararası AS Çalışma Grubu (ASAS)’nun AS’te tedaviye yanıt kriterleri olan ASAS-20, ASAS-40, ASAS-5/6, ASAS parsiyel remisyon ve BASDAI-50 yanıtı ile belirlendi. Bulgular: 6 aylık etanercept tedavisinden sonra klinik ve laboratuvar değerlendirme parametrelerinin tümünde istatistiksel olarak anlamlı iyileşme görüldü. Ayrıca 18 hastada ASAS-20, 16 hastada ASAS-40, 14 hastada ASAS-5/6, 10 hastada ASAS parsiyel remisyon ve 16 hastada BASDAI-50 yanıtları elde edildi. Ciddi yan etki nedeni ile tedaviyi bırakmak zorunda kalan hasta olmadı. 4 hastada enjeksiyon yeri reaksiyonu, 1 hastada eritem, 1 hastada bulantı-kusma şikayeti tespit edildi. Sonuç: Bulgularımız, etanercept tedavisinin AS’li hastalarda etkili olduğunu ve güvenle kullanılabileceğini göstermektedir.
FULL TEXT (PDF): 
PDF icon arastirmax-ankilozan-spondilitli-hastalarda-etanercept-tedavisinin-etkinligi-guvenilirligi.pdf
  • 2
91-96
  • Turkish

REFERENCES

References: 

1. Brandt J, Khariouzov A, Listing J, et al. Six-month results of a
double-blind, placebo-controlled trial of etanercept treatment
in patients with active ankylosing spondylitis. Arthritis Rheum
2003;48:1667-75.
2. Davis JC, van der Heijde DM, Braun J, et al. Sustained
durability and tolerability of etanercept in ankylosing
spondylitis for 96 weeks. Ann Rheum Dis 2005;64:1557-62.
3. Landewe R, Rump B, van der Heijde D, et al. Which patients
with ankylosing spondylitis should be treated with tumour
necrosis factor inhibiting therapy? A survey among Dutch
rheumatologists. Ann Rheum Dis 2004;63:530-4.
4. van der Linden S, van Tubergen A, Hidding A. Physiotherapy
in ankylosing spondylitis: what is the evidence? Clin Exp
Rheumatol 2002;20(6 Suppl 28):60-4.
5. Francois RJ, Neure L, Sieper J, et al. Immunohistological
examination of open sacroiliac biopsies of patients with
ankylosing spondylitis: detection of tumour necrosis factor
alpha in two patients with early disease and transforming
growth factor beta in three more advanced cases. Ann Rheum
Dis 2006;65:713-20.
6. McCormack PL, Wellington K. Etanercept: in ankylosing
spondylitis. BioDrugs 2004;18:199-205; discussion 206.
7. van der Heijde D, Kivitz A, Schiff MH, et al. Efficacy and
safety of adalimumab in patients with ankylosing spondylitis:
results of a multicenter, randomized, double-blind, placebocontrolled
trial. Arthritis Rheum 2006;54:2136-46.
8. Brandt J, Listing J, Haibel H, et al. Long-term efficacy and
safety of etanercept after readministration in patients with
active ankylosing spondylitis. Rheumatology (Oxford)
2005;44:342-8.
9. Inman RD, Clegg DO, Davis JC, et al. Etanercept in adult
patients with early onset ankylosing spondylitis. J Rheumatol
2006;33:1634-6.
10. Davis JC, van der Heijde D, Dougados M, et al. Reductions in
health-related quality of life in patients with ankylosing
spondylitis and improvements with etanercept therapy.
Arthritis Rheum 2005;53:494-501.
11. Davis JC, Jr., Van Der Heijde D, Braun J, et al. Recombinant
human tumor necrosis factor receptor (etanercept) for treating
ankylosing spondylitis: a randomized, controlled trial. Arthritis
Rheum 2003;48:3230-6.
12. van der Linden S, Valkenburg HA, Cats A. Evaluation of
diagnostic criteria for ankylosing spondylitis. A proposal for
modification of the New York criteria. Arthritis Rheum
1984;27:361-8.
13. Temekonidis TI, Alamanos Y, Nikas SN, et al. Infliximab
therapy in patients with ankylosing spondylitis: an open label
12 month study. Ann Rheum Dis 2003;62:1218-20.
14. Akkoc Y, Karatepe AG, Akar S, et. al. A Turkish version of
the Bath Ankylosing Spondylitis Disease Activity Index:
reliability and validity. Rheumatol Int 2005;25 280-4.
15. Karatepe AG, Akkoc Y, Akar S, et al. The Turkish versions of
the Bath Ankylosing Spondylitis and Dougados Functional
Indices: reliability and validity. Rheumatol Int 2005;25:612-8.
16. Daltroy LH, Larson MG, Roberts NW, et al. A modification of
the Health Assessment Questionnaire for the
spondyloarthropathies. J Rheumatol 1990;17:946-50.
17. Jenkinson TR, Mallorie PA, Whitelock HC, et al. Defining
spinal mobility in ankylosing spondylitis (AS). The Bath AS
Metrology Index. J Rheumatol 1994;21:1694-8.
18. Doward LC, Spoorenberg A, Cook SA, et al. Development of
the ASQoL: a quality of life instrument specific to ankylosing
spondylitis. Ann Rheum Dis 2003;62:20-6.
19. Heuft-Dorenbosch L, Spoorenberg A, van Tubergen A, et al.
Assessment of enthesitis in ankylosing spondylitis. Ann Rheum
Dis 2003;62:127-32.
20. van der Heijde D, Pangan AL, Schiff MH, et al. Adalimumab
effectively reduces the signs and symptoms of active
ankylosing spondylitis in patients with total spinal ankylosis.
Ann Rheum Dis 2008;67:1218-21.
21. Cohen JS. Clinical and laboratory improvement in ankylosing
spondylitis after treatment with etanercept: a case report. J Clin
Rheumatol 2000;6:221-4.
22. Choi CB, Kim TJ, Park HJ, et. al. Safety and clinical responses
in ankylosing spondylitis after three months of etanercept
therapy. J Korean Med Sci 2008;23:852-6.
23. Konttinen L, Tuompo R, Uusitalo T, et al. Anti-TNF therapy
in the treatment of ankylosing spondylitis: the Finnish
experience. Clin Rheumatol 2007;26:1693-700.
24. Bodur H, Ataman S, Akbulut L, et al. Characteristics and
medical management of patients with rheumatoid arthritis and
ankylosing spondylitis. Clin Rheumatol 2008;27:1119-25.
25. Gorman JD, Sack KE, Davis JC, Jr. Treatment of ankylosing
spondylitis by inhibition of tumor necrosis factor alpha. N
Engl J Med 2002;346:1349-56.
26. Lee SH, Lee YA, Hong SJ, et. al. Etanercept 25 mg/week is
effective enough to maintain remission for ankylosing
spondylitis among Korean patients. Clin Rheumatol
2008;27:179-81.
27. Braun J, McHugh N, Singh A, et al. Improvement in patientreported
outcomes for patients with ankylosing spondylitis
treated with etanercept 50 mg once-weekly and 25 mg twiceweekly.
Rheumatology (Oxford) 2007;46:999-1004.
28. Bresnihan B, Cunnane G. Infection complications associated
with the use of biologic agents. Rheum Dis Clin North Am
2003;29:185-202.
29. Weisman MH. What are the risks of biologic therapy in
rheumatoid arthritis? An update on safety. J Rheumatol Suppl
2002;65:33-8.
30. Calin A, Dijkmans BA, Emery P, et al. Outcomes of a
multicentre randomised clinical trial of etanercept to treat
ankylosing spondylitis. Ann Rheum Dis 2004;63:1594-600.

Thank you for copying data from http://www.arastirmax.com